Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged alzheimer's disease mice

Journal of Alzheimer's Disease

Volumn 17, Issue 3, 2009, Pages 661-680

  Arendash, Gary W ^a,b   Mori, Takashi ^c   Cao, Chuanhai ^a,b   Mamcarz, Malgorzata ^a,b   Runfeldt, Melissa ^a,b   Dickson, Alexander ^a,b   Rezai Zadeh, Kavon ^d   Tan, Jun ^d   Citron, Bruce A ^d,e   Lin, Xiaoyang ^a,b   Echeverria, Valentina ^d,e   Potter, Huntington ^a,b,d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Alzheimer's transgenic mice; Amyloid ; Caffeine; Cognitive impairment; Memory; Treatment

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; CAFFEINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DRINKING WATER; GAMMA SECRETASE; GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PRESENILIN 1;

AGED; AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN TISSUE; COFFEE; COGNITIVE DEFECT; CONTROLLED STUDY; ENTORHINAL CORTEX; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; HUMAN; IMMUNOHISTOCHEMISTRY; MAZE TEST; MEMORY DISORDER; MOUSE; NERVE CELL CULTURE; NONHUMAN; OPEN FIELD BEHAVIOR; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORIMOTOR FUNCTION; TASK PERFORMANCE; TRANSGENIC MOUSE; WORKING MEMORY;

EID: 67849083449     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1087     Document Type: Article

References (65)

1. Fredholm B, Bättig K, Holmé J, Nehlig A, Zvartau E (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51, 83-133.
2. Ruhl C, Everhart J (2005) Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 128, 24-32.
3. Higdon J, Frei B (2006) Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr 46, 101-123.
4. Ross G, Abbott R, Petrovitch H, Morens D, Grandinetti A, Tung K, Tanner C, Masaki K, Blanchette P, Curb J, Popper J, White L (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283, 2674-2679.
5. Hernán M, Takkouche B, Caamaño-Isorna F, Gestal-Otero J (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52, 276-284.
6. Ritchie K, Carrière I, de Mendonca A, Portet F, Dartigues J, Rouaud O, Barberger-Gateau P, Ancelin M (2007) The neuro-protective effects of caffeine: a prospective population study (the Three City Study). Neurology 69, 536-545.
7. van Gelder B, Buijsse B, Tijhuis M, Kalmijn S, Giampaoli S, Nissinen A, Kromhout D (2007) Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur J Clin Nutr 61, 226-232.
8. Eckelinen M, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M (2008) Midlife coffee and tea drinking and the risk of late-life dementia: A population-based CAIDE study. J Alzheimer's Dis 16, 85-91
9. Maia L, de Mendonça A (2002) Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 9, 377-382.
10. Rosso A, Lippa C, Mossey J (2008) Caffeine: Neuroprotective Functions in Cognition and Alzheimer's Disease. Am J Alzheimers Dis Other Demen 23, 417-422.
11. Arendash G, Garcia M, Costa D, Cracchiolo J, Wefes I, Potter H (2004) Environmental enrichment improves cognition in aged Alzheimer's transgenic mice despite stable beta-amyloid deposition. Neuroreport 15, 1751-1754.
12. Arendash G, Lewis J, Leighty R, McGowan E, Cracchiolo J, Hutton M, Garcia M (2004) Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res 1012, 29-41.
13. Arendash G, Schleif W, Rezai-Zadeh K, Jackson E, Zacharia L, Cracchiolo J, Shippy D, Tan J (2006) Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 142, 941-952.
14. Keller E, Fu Z, Brennan M (2004) The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem Pharmacol 68, 1049-1053.
15. Mei M, Su B, Harrison K, Chao M, Siedlak S, Previll L, Jackson L, Cai D, Zhu X (2006) Distribution, levels and phosphorylation of Raf-1 in Alzheimer's disease. J Neurochem 99, 1377-1388.
16. Woodgett J (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9, 2431-2438.
17. Grimes C, Jope R (2001) CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 78, 1219-1232.
18. Grimes C, Jope R (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65, 391-426.
19. Hernández F, Borrell J, Guaza C, Avila J, Lucas J (2002) Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 83, 1529-1533.
20. Phiel C, Wilson C, Lee V, Klein P (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439.
21. Takashima A (2006) GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 9, 309-317.
22. Jensen M, Mottin M, Cracchiolo J, Leighty R, Arendash G (2005) Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 130, 667-684.
23. Arendash G, Jensen M, Salem N, Hussein N, Cracchiolo J, Dickson A, Leighty R, Potter H (2007) A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice. Neuroscience 149, 286-302.
24. Cracchiolo J, Mori T, Nazian S, Tan J, Potter H, Arendash G (2007) Enhanced cognitive activity-over and above social or physical activity-is required to protect Alzheimer's mice against cognitive impairment, reduce Abeta deposition, and increase synaptic immunoreactivity. Neurobiol Learn Mem 88, 277-294.
25. Leighty R, Nilsson L, Potter H, Costa D, Low M, Bales K, Paul S, Arendash G (2004) Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition. Behav Brain Res 153, 107-121.
26. Mori T, Town T, Tan J, Yada N, Horikoshi Y, Yamamoto J, Shimoda T, Kamanaka Y, Tateishi N, Asano T (2006) Arundic acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J Pharmacol Exp Ther 318, 571-578.
27. Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell R, Mullan M (2002) Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 5, 1288-1293.
28. Leighty R, Runfeldt M, Berndt D, Schleif W, Cracchiolo J, Potter H, Arendash G (2008) Use of artificial neural networks to determine cognitive impairment and therapeutic effectiveness in Alzheimer's transgenic mice. J Neurosci Methods 167, 358-366.
29. Austin L, Arendash G, Gordon M, Diamond D, DiCarlo G, Dickey C, Ugen K, Morgan D (2003) Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. Behav Neurosci 117, 478-484.
30. Ethell D, Shippy D, Cao C, Cracchiolo J, Runfeldt M, Blake B, Arendash G (2006) Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis 23, 351-361.
31. King D, Arendash G (2002) Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav 75, 627-642.
32. Li S, Janosch P, Tanji M, Rosenfeld G, Waymire J, Mischak H, Kolch W, Sedivy J (1995) Regulation of Raf-1 kinase activity by the 14-3-3 family of proteins. EMBO J 14, 685-696.
33. Bourne K, Ferrari D, Lange-Dohna C, Rossner S, Wood T, Perez-Polo J (2007) Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res 85, 1194-1204.
34. Rezai-Zadeh K, Shytle R, Bai Y, Tian J, Hou H, Mori T, Zeng J, Obregon D, Town T, Tan J (2009) Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production. J Cell Mol Med 13, 574-588.
35. Nehlig A, Daval J, Debry G (1992) Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev 17, 139-170.
36. Massey L (1998) Caffeine and the elderly. Drugs Aging 13, 43-50.
37. Dall'Igna O, Porciúncula L, Souza D, Cunha R, Lara D, Dall'lgna O (2003) Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 138, 1207-1209.
38. Cunha G, Canas P, Melo C, Hockemeyer J, Müller C, Oliveira C, Cunha R (2008) Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. Exp Neurol 210, 776-781.
39. Dall'Igna O, Fett P, Gomes M, Souza D, Cunha R, Lara D (2007) Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol 203, 241-245.
40. Fisone G, Borgkvist A, Usiello A (2004) Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 61, 857-872.
41. Daly J (2007) Caffeine analogs: biomedical impact. Cell Mol Life Sci 64, 2153-2169.
42. Chong H, Lee J, Guan K (2001) Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J 20, 3716-3727.
43. Finco T, Baldwin A (1993) Kappa B site-dependent induction of gene expression by diverse inducers of nuclear factor kappa B requires Raf-1. J Biol Chem 268, 17676-17679.
44. Gilmore T (2006) Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25, 6680-6684.
45. Valerio A, Boroni F, Benarese M, Sarnico I, Ghisi V, Bresciani L, Ferrario M, Borsani G, Spano P, Pizzi M (2006) NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur J Neurosci 23, 1711-1720.
46. Horrigan L, Kelly J, ConnorT (2004) Caffeine suppresses TNF-alpha production via activation of the cyclic AMP/protein kinase A pathway. Int Immunopharmacol 4, 1409-1417.
47. Al-Wadei H, Takahashi T, Schuller H (2006) Caffeine stimulates the proliferation of human lung adenocarcinoma cells and small airway epithelial cells via activation of PKA, CREB and ERK1/2. Oncol Rep 15, 431-435.
48. D'Angelo G, Lee H, Weiner R (1997) cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 67, 353-366.
49. Echeverria V, Burgess S, Gamble-George J, Zeitlin R, Lin X, Cao C, Arendash GW (2009) Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric-oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience, doi: 10.1016/j.neuroscience. 2009.05.019.
50. Costa D, Cracchiolo J, Bachstetter A, Hughes T, Bales K, Paul S, Mervis R, Arendash G, Potter H (2007) Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms. Neurobiol Aging 28, 831-844.
51. Gong B, Vitolo O, Trinchese F, Liu S, Shelanski M, Arancio O (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114, 1624-1634.
52. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104, 1433-1439.
53. Twomey C, McCarthy J (2006) Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate. FEBS Lett 580, 4015-4020.
54. Lucas J, Hernández F, Gómez-Ramos P, Morán M, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20, 27-39.
55. Engel T, Hernández F, Avila J, Lucas J (2006) Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 26, 5083-5090.
56. Potter H, Wefes I, Nilsson L (2001) The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol Aging 22, 923-930.
57. Azam S, Hadi N, Khan N, Hadi S (2003) Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. Med Sci Monit 9, BR325-330.
58. Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, Mullan M (2004) Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res 999, 53-61.
59. Juárez-Méndez S, Carretero R, Martínez-Tellez R, Silva-Gómez A, Flores G (2006) Neonatal caffeine administration causes a permanent increase in the dendritic length of prefrontal cortical neurons of rats. Synapse 60, 450-455.
60. Lee W, Anwyl R, Rowan M (1987) Caffeine inhibits post-tetanic potentiation but does not alter long-term potentiation in the rat hippocampal slice. Brain Res 426, 250-256.
61. Lu K, Wu S, Gean P (1999) Promotion of forskolin-induced long-term potentiation of synaptic transmission by caffeine in area CA1 of the rat hippocampus. Chin J Physiol 42, 249-253.
62. Martín E, Buño W (2003) Caffeine-mediated presynaptic long-term potentiation in hippocampal CA1 pyramidal neurons. J Neurophysiol 89, 3029-3038.
63. Chen X, Gawryluk J, Wagener J, Ghribi O, Geiger J (2008) Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J Neuroinflammation 5, 12.
64. Zipser B, Johanson C, Gonzalez L, Berzin T, Tavares R, Hulette C, Vitek M, Hovanesian V, Stopa E (2007) Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 28, 977-986.
65. Ujiie M, Dickstein D, Carlow D, Jefferies W (2003) Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10, 463-470.